Genetic Leap

Genetic Leap is an AI-native techbio company that focuses on developing RNA-targeted genetic medicines. The company's proprietary AI platform is designed to revolutionize the approach to drugging RNA, addressing challenges that have historically made it difficult to target effectively. Genetic Leap's technology aims to find causal factors in diseases and correct them using precision RNA therapy that is safe, convenient, and reversible. The platform is capable of drugging RNA at its sequence using oligonucleotides or at its structure using small molecules. Genetic Leap is advancing a pipeline that includes both internal and partnered programs, targeting novel and established disease targets that were previously considered undruggable.

Key customers and partnerships

Genetic Leap entered into a research collaboration with Eli Lilly and Company to develop genetic medicine therapeutics. The partnership leverages Genetic Leap's RNA-targeted AI platform to generate oligonucleotide drugs against targets selected by Lilly in high-priority therapeutic areas. Genetic Leap also established a research collaboration with Astellas Pharma, Inc. to develop novel RNA-targeted small molecule therapeutic candidates against an undisclosed oncology target. These collaborations demonstrate the company's ability to attract major pharmaceutical partners and validate its AI-driven approach to drug discovery.